Replies to post #13913 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I wouldn’t take the nominal 15% discount in list price too literally.

[DewDiligence]

Amended NVS-MNTA Lovenox agreement, calling for 50/50 profit split instead of a royalty:

http://www.sec.gov/Archives/edgar/data/1235010/000110465915046306/a15-14315_1ex10d1.htm

This change will be economically material to MNTA only if NVS/MNTA ultimately prevail in the Lovenox patent case by circumventing the H-W Safe Harbor defense.

[floblu14]

I wonder if it's the slight discount that has spooked investors.

Might be more of Teva's BS -

Teva spokesperson Denise Bradley said Teva will seek an en banc review of the decision by CAFC.

http://www.biocentury.com/dailynews/topstory/2015-06-18/generic-copaxone-launched-after-cafc-invalidates-teva-patent

[tony111]

I am not surprised at all at the price action today. Shorting biotech stocks on FDA approval most of the time makes you money. I can think of a couple examples right away ARNA, VUVS, OREX, KERX, DNDN. There is no imminent upside for MNTA now, making it a good timing for short term investors to exit. MNTA now has ~1.7B market cap it is certainly not cheap.